Ozempic(semaglutide), a new once-weekly GLP-1 analogue injection for the treatment of type 2 diabetes, is now available in the UK, Novo Nordisk UK has announced.
It works by mimicking the function of the GLP-1 (human glucagon-like peptide-1) hormone produced in the gut that lowers post-meal blood glucose levels and also slows glucose absorption into the bloodstream.
Ozempicshould be used alongside diet and exercise, as monotherapy when metformin is considered inappropriate due to intolerance or contraindications or in addition to other medicinal products for the treatment of diabetes, when type 2 diabetes is insufficiently controlled.
Cardiovascular disease is the number one cause of death and disability in type 2 diabetes worldwide. Leading charity Diabetes UK recently warned that people with type 2 diabetes are up to twice more likely to die prematurely from avoidable complications than those without the condition. In the latest data available from NHS Digital (2016/17) 33% of people living with type 2 diabetes did not meet their blood glucose (HbA1c) target of 7.5%4. Alongside this nine out of 10 are overweight or obese.
The EU licensing of Ozempicis based on results from the SUSTAIN clinical trial programme which consistently demonstrated:
superior glycaemic control compared to dulaglutide, exenatide once weekly, sitagliptin and insulin glargine U100
superior and sustained weight loss compared to dulaglutide, exenatide once weekly, sitagliptin and insulin glargine U100
cardiovascular benefits vs placebo both in addition to standard of care in people with type 2 diabetes at high risk for CV events
Ozempichas received positive recommendation by the two UK health technology assessment (HTA) bodies, All Wales Medicines Strategy Group (AWMSG) and Scottish Medicines Consortium (SMC). Ozempicis recommended as a treatment option for restricted use within NHS Wales and NHS Scotland in the treatment of insufficiently controlled type 2 diabetes mellitus in adults as an add-on therapy to oral antidiabetic medicines or basal insulin.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.